UK NCRI AML19 Trial – Liposomal daunorubicin and cytarabine had a significant survival benefit
In this MEDtalk, Jad Othman, Department of Medical and Molecular Genetics, King’s College London, London, United Kingdom, presents the UK NCRI AML19 Trial results. This trial shows that liposomal daunorubicin and cytarabine had a significant survival benefit over fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor (FLAG-IDA regime) in young high-risk patients with secondary AML/MDS as defined by the presence of myelodysplasia-related gene mutations.
